title: Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
authors.forename: Anja Gunda
authors.initials: AG
authors.lastname: Jung
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Horny
authors.forename: Karl
authors.initials: K
authors.lastname: Sotlar
authors.forename: Tobias
authors.initials: T
authors.lastname: Overbeck
authors.forename: Michael Peter
authors.initials: MP
authors.lastname: Schön
authors.forename: Undine
authors.initials: U
authors.lastname: Lippert
mesh_terms: D015502:Absorptiometry, Photon; D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D034721:Mastocytosis, Systemic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D010014:Osteolysis / Q000150:complications / Q000000981:diagnostic imaging*; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate